MedTrace Logo

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

NCT06697366 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-11-20

No results posted yet for this study

Summary

Evaluating the efficacy and safety of irinotecan liposome injection in combination with Sintilimab in the second-line treatment of progressive gastric cancer

Conditions

Interventions

DRUG

Irinotecan liposome injection Ⅱ

56.6 mg/m2，Q3W

DRUG

Sintilimab

200mg，Q3W

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Hao Li · Ruijin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-20
Primary Completion
2026-05-20
Completion
2026-11-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06697366 on ClinicalTrials.gov